- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the U.S. for ambulatory Duchenne patients. Expansion to non-ambulatory patients is uncertain after the ENVISION trial closure; a safety study and FDA engagement in Q1 2027 will determine the path forward.
- Why 4/10
- ELEVIDYS is already approved and commercialized with no pending PDUFA or pivotal readout. The next hard catalyst is the Q1 2027 FDA engagement on the non-ambulatory safety study, roughly 4-5 months out, but this is a regulatory discussion rather than a binary approval decision. The drug is a major revenue driver for Sarepta, but the company also has an exon-skipping franchise, so concentration is not total. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5.
Watch for the Q1 2027 FDA engagement on the sirolimus safety study for non-ambulatory patients. A constructive outcome could open a path to label expansion and de-risk the safety narrative, while a negative FDA response would reinforce concerns about ELEVIDYS' risk profile and limit its addressable market. Also monitor quarterly revenue trends for signs of stabilization or further erosion in the approved ambulatory population.
Price Chart
Executive Summary
ELEVIDYS (delandistrogene moxeparvovec) is Sarepta Therapeutics' FDA-approved one-time gene therapy for Duchenne muscular dystrophy. It generated significant revenue but faces serious headwinds: three patient deaths led to closure of the ENVISION Phase 3 trial in non-ambulatory patients, the FDA added a black-box warning for acute liver injury in August 2026, and the company had a public dispute with the FDA in July 2025 over shipping the drug. The stock trades near $18, down from a 52-week high of $24.68, with a mixed analyst consensus (12 buy/strong buy, 13 hold, 6 sell/strong sell). The next catalyst is a Q1 2027 FDA engagement on a safety study for non-ambulatory patients.
How It Works
A one-time gene therapy given as an intravenous infusion. It uses a harmless virus (AAV) to deliver a working copy of a shortened but functional version of the dystrophin gene (called micro-dystrophin) directly into muscle cells. Boys with Duchenne muscular dystrophy lack functional dystrophin, which causes progressive muscle degeneration. The therapy aims to restore enough dystrophin production to slow or halt disease progression.
Trial Status
ELEVIDYS received accelerated FDA approval in June 2023 for ambulatory boys aged 4-5 with DMD, followed by traditional approval with an expanded label in June 2024 covering a broader ambulatory population. The confirmatory ENVISION Phase 3 trial in non-ambulatory patients was closed in November 2026 after three patient deaths linked to acute liver failure. Sarepta is now planning a 25-patient safety study combining ELEVIDYS with the immunosuppressant sirolimus, with FDA engagement expected in Q1 2027. New data presented at the 2026 World Muscle Society congress showed durable functional benefit in older ambulatory patients (ages 8-12) over two years versus external controls.
The Two-Sided Case
Upcoming Catalysts
- Q1 2027: FDA engagement on the 25-patient sirolimus safety study for non-ambulatory Duchenne patients
- Ongoing commercial execution and quarterly revenue reports for ELEVIDYS in the approved ambulatory indication
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sarepta Therapeutics, Inc. 8-K SRPT ·Originating report